actinium has been researched along with abt-199 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, KJH; Dadachova, E; Dawicki, W; Garg, R; Geoghegan, EM; Ludwig, DL | 1 |
1 other study(ies) available for actinium and abt-199
| Article | Year |
|---|---|
225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Topics: Actinium; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |